Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients

• 資料種別: 記事
• タイトル: Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients
• 著者標目: Masataka Tsuge; Eisuke Murakami; Michio Imamura; Hiromi Abe; Daiki Miki; Nobuhiko Hiraga; Shoichi Takahashi; Hidenori Ochi; C. Nelson Hayes; Hiroyuki Ginba; Kazuhiro Matsuyama; Hiroiku Kawakami; Kazuaki Chayama
• 出版年月日等: 2013-02-09
• 出版年（W3CDTF）: 2013-02-09
• タイトル（掲載誌）: Journal of Gastroenterology
• 巻号年月日等（掲載誌）: 48 10
• 掲載巻: 48
• 掲載号: 10
• 掲載ページ: 1188-1204
• 掲載年月日（W3CDTF）: 2013-02-09
• ISSN（掲載誌）: 09441174
• 出版事項（掲載誌）: Springer Science and Business Media LLC
• 件名標目: Adult; Male; Hepatitis B virus; Alanine Transaminase; Middle Aged; Real-Time Polymerase Chain Reaction; Antiviral Agents; Hepatitis B, Chronic; Japan; Recurrence; DNA, Viral; Humans; RNA, Viral; Female; Hepatitis B e Antigens; Biomarkers; Aged
• 対象利用者: 一般
• 標準番号（その他）: PMID : 23546558
• DOI: 10.1007/s00535-012-0737-2; https://doi.org/10.1007/s00535-012-0737-2
• 作成日（W3CDTF）: 2013-02-09
• 著作権情報: http://www.springer.com/tdm
• 関連情報（URI）: http://link.springer.com/content/pdf/10.1007/s00535-012-0737-2.pdf; http://link.springer.com/article/10.1007/s00535-012-0737-2/fulltext.html; http://link.springer.com/content/pdf/10.1007/s00535-012-0737-2
• 参照: Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy; https://cir.nii.ac.jp/crid/1360004231260316544; Deep sequencing analysis of serum hepatitis B virus‐RNA during nucleot(s)ide analogue therapy; https://cir.nii.ac.jp/crid/1360009142905954944; Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1360025430173265280; Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones; https://cir.nii.ac.jp/crid/1360567182238880768; On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy; https://cir.nii.ac.jp/crid/1360846645717180288
• 参照: Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present; https://cir.nii.ac.jp/crid/1360011145278565888; Hepatitis B Virus Infection — Natural History and Clinical Consequences; https://cir.nii.ac.jp/crid/1360292619950743808; Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1360565164508497024; Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1360574095776656512; Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine†; https://cir.nii.ac.jp/crid/1360574096568599040; Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1360848660687481088; Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan; https://cir.nii.ac.jp/crid/1360855569278282752; Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy; https://cir.nii.ac.jp/crid/1360855569790044032; Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children; https://cir.nii.ac.jp/crid/1361137044036436736; Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection; https://cir.nii.ac.jp/crid/1361137045315375232; Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus Load; https://cir.nii.ac.jp/crid/1361137045509395840; Antiviral drug-resistant HBV; https://cir.nii.ac.jp/crid/1361699993483932160; A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361699993865715200; Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC); https://cir.nii.ac.jp/crid/1361699996200501760; Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy; https://cir.nii.ac.jp/crid/1361981468392545536; Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan; https://cir.nii.ac.jp/crid/1361981469184338432; Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†; https://cir.nii.ac.jp/crid/1361981469442883840; Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment; https://cir.nii.ac.jp/crid/1361981469488158976; A One-Year Trial of Lamivudine for Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1362262945246144768; Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1362262946294234752; Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine; https://cir.nii.ac.jp/crid/1362262946330272768; Management of chronic hepatitis B; https://cir.nii.ac.jp/crid/1362544418380100864; Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up; https://cir.nii.ac.jp/crid/1362544418999024000; Successful treatment of an entecavir‐resistant hepatitis B virus variant; https://cir.nii.ac.jp/crid/1362544419163194112; Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B; https://cir.nii.ac.jp/crid/1362544419333357568; Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients; https://cir.nii.ac.jp/crid/1362544419430145536; Hepatitis B Virus Resistance to Nucleos(t)ide Analogues; https://cir.nii.ac.jp/crid/1362544420283809408; Molecular biology of hepadnavirus replication; https://cir.nii.ac.jp/crid/1362825893713551360; Clinical aspects of hepatitis B virus infection; https://cir.nii.ac.jp/crid/1362825895282378240; Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas; https://cir.nii.ac.jp/crid/1363107368582391424; The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma.; https://cir.nii.ac.jp/crid/1363388844727764352; DRINKING HABITS OF SUBJECTS WITH HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE: PREVALENCE AND EFFECT ON CLINICAL, VIROLOGICAL AND PATHOLOGICAL ASPECTS; https://cir.nii.ac.jp/crid/1363670319018334720; Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine; https://cir.nii.ac.jp/crid/1363951794295554176
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org; CiNii Articles; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja
• NII論文ID: 20001417118

• 要約等: Treatment for chronic hepatitis B has improved drastically with the use of nucleot(s)ide analogues (NAs). However, NA therapy typically fails to elimi...